Abstract | PURPOSE OF REVIEW: Most patients affected by lung cancer are treated with chemotherapy, and hence are at risk of myelosuppression. Hematopoietic growth factors have a relevant role in this setting, as they can improve quality of life, reduce the rate of chemotherapy-induced complications and allow the administration of full-dose chemotherapy. RECENT FINDINGS: SUMMARY:
|
Authors | Carlo Genova, Erika Rijavec, Francesco Grossi |
Journal | Current opinion in oncology
(Curr Opin Oncol)
Vol. 28
Issue 2
Pg. 135-44
(Mar 2016)
ISSN: 1531-703X [Electronic] United States |
PMID | 26742020
(Publication Type: Journal Article, Review)
|
Chemical References |
- Hematinics
- Hematologic Agents
- Hematopoietic Cell Growth Factors
|
Topics |
- Anemia
(chemically induced, drug therapy, prevention & control)
- Chemotherapy-Induced Febrile Neutropenia
(drug therapy, prevention & control)
- Hematinics
(therapeutic use)
- Hematologic Agents
(therapeutic use)
- Hematopoietic Cell Growth Factors
(therapeutic use)
- Humans
- Lung Neoplasms
(drug therapy)
|